Ipca Labs Q3 Review - Domestic Formulation Outperforms; API, Branded Exports Underperforms: Motilal Oswal
Work-in-progress to strengthen U.S. generics prospects16-02-2024
16-02-2024
IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for Conference Call held on 15th February, 2024.16-02-2024
Ipca Laboratories Results Earnings Call for Q3FY24
Conference Call with Ipca Laboratories Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.15-02-2024
IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of the Consolidated Unaudited Financial Results for the 3rd quarter and 9 months ended 31st December, 202315-02-2024
Ipca Labs Q3 Profit Up 67% At Rs 180 Crore
The drugmaker had reported a net profit of Rs 108 crore for October-December FY23.14-02-2024
IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Dr. (Ms.) Swati Patankar as an Independent Director14-02-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Ipca Laboratories Ltd.
Pharmaceuticals company Ipca Laboratories announced Q3FY24 & 9MFY24 results: Q3FY24 Financial Highlights: Standalone Net Total Income increased by 4% to Rs 1,523.72 crore. Consolidated Net Total Income surged by 32% to Rs 2,075.31 crore. Indian formulations income grew by 11% to Rs 779.61 crore. Exports Income rose by 1% to Rs 640.34 crore. Standalone EBITDA margin (before forex gain/loss and other income) stood at 18.55% in Q3FY24, compared to 15.77% in Q3FY23. Consolidated EBITDA margin (before forex gain/loss, other income, and exceptional items) stood at 16.12% in Q3FY24, compared to 15.00% in Q3FY23. Standalone Net Profit increased by 19% to Rs 136.94 crore. Consolidated Net Profit surged by 67% to Rs 179.88 crore. 9MFY24 Financial Highlights: Standalone Net Total Income grew by 6% to Rs 4,752.03 crore. Consolidated Net Total Income increased by 20% to Rs 5,777.88 crore. Indian formulations income rose by 12% to Rs 2,407.33 crore. Exports Income increased by 1% to Rs 1,976.32 crore. Standalone EBITDA margin (before forex gain/loss, other income, and Unichem acquisition cost) stood at 19.55% in 9MFY24, compared to 17.63% in 9MFY23. Consolidated EBITDA margin (before forex gain/loss, other income, Unichem acquisition cost, and exceptional items) stood at 17.34% in 9MFY24, compared to 16.64% in 9MFY23. Standalone Net Profit grew by 11% to Rs 465.65 crore. Consolidated Net Profit increased by 24% to Rs 487.76 crore. Result PDF14-02-2024
IPCA LABORATORIES LTD. - 524494 - Standalone And Consolidated Q3FY24 Results And Press Release
Standalone and Consolidated Q3FY24 Results and Press Release14-02-2024
IPCA LABORATORIES LTD. - 524494 - Board Meeting Outcome for Outcome Of Board Meeting Held On 14.02.2024
Outcome of Board Meeting held on 14.02.202414-02-2024
IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call to discuss the Company's Q3 FY24 earnings and business update to be held on Thursday, 15th February, 2024 at 15.30 hrs IST.08-02-2024